Payment overview · 2025
General Payments
$213.25
9 reported records · 6 companies
Healthcare provider profile · identity verified
Nancy Shupe, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALTON, KY · NPI 1033146881
Verified facts
What the public records show
CMS Open Payments records show Nancy Shupe, M.D. received $213.25 in general payments during 2025 across 9 reported records.
Vanda Pharmaceuticals Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.43 | 54.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.65 | 13.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.31 | 10.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.10 | 8.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.07 | 8.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.69 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.25 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $115.43 | 4 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $115.43 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 100 |
| Lisinopril | Lisinopril | 255 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 70 |
| Omeprazole | Omeprazole | 210 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 60 |
| Sertraline Hcl | Sertraline Hcl | 184 | 56 |
| Lorazepam | Lorazepam | 170 | 31 |
| Metformin Hcl Er | Metformin Hcl | 154 | 48 |
| Gabapentin | Gabapentin | 144 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 39 |
| Furosemide | Furosemide | 117 | 45 |
| Simvastatin | Simvastatin | 114 | 27 |
| Meloxicam | Meloxicam | 113 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 37 |
| Losartan Potassium | Losartan Potassium | 106 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 30 |
| Valsartan | Valsartan | 96 | 24 |
| Alprazolam | Alprazolam | 93 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 14 |
| Potassium Chloride | Potassium Chloride | 86 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 40 |
| Trazodone Hcl | Trazodone Hcl | 75 | 21 |
| Bupropion Xl | Bupropion Hcl | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 19 |
| Tramadol Hcl | Tramadol Hcl | 71 | 21 |
| Ozempic | Semaglutide | 70 | 14 |
| Prednisone | Prednisone | 68 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 20 |
| Glimepiride | Glimepiride | 67 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 26 |
| Montelukast Sodium | Montelukast Sodium | 66 | 19 |
| Eliquis | Apixaban | 65 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 22 |
| Allopurinol | Allopurinol | 58 | 15 |
| Spironolactone | Spironolactone | 58 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 17 |
| Carvedilol | Carvedilol | 53 | 18 |
| Cephalexin | Cephalexin | 52 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Metformin Hcl | Metformin Hcl | 48 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Azithromycin | Azithromycin | 39 | 31 |
| Januvia | Sitagliptin Phosphate | 39 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Lovastatin | Lovastatin | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Fluconazole | Fluconazole | 33 | 20 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Famotidine | Famotidine | 25 | 12 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Estradiol | Estradiol | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 12 |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 14 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.25 · 9 records | Vanda Pharmaceuticals Inc. | FANAPT, FREESTYLE LIBRE 3, HETLIOZ, Ozempic, REXULTI, Rybelsus, SPRAVATO, Sunosi | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error